Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease

Inclusion Criteria: * Subject is between 21 - 65 years of age. * Subject has a history of heartburn, regurgitation or both for \> 6 months prompting physician recommendation of continual daily use of PPI before study entry. * Baseline GERD-HRQL heartburn score of ≥ 20 off PPI assessed during the run-in phase. * Subject has an American Society of Anesthesiologists (ASA) Physical Status Classification I or II (or comparable local classification if any). * Subject has demonstrated satisfactory symptomatic response to a previous course of GERD therapy (≥ 2 weeks); GERD HRQL heartburn score improvement of ≥ 10 on therapy as assessed during the run in phase. * Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry off antisecretory therapy performed within 6 months of enrollment; pH \< 4 for \> 5% of total or \> 3% of supine time. * Subject has a resting LES end expiratory pressure \> 5mm Hg and \< 15 mm Hg on a high resolution manometry within 6 months of enrollment. * Subject has esophagitis ≤ Grade C (LA classification) on upper endoscopy within 6 months of enrollment. * Subject has esophageal body contraction amplitude \> 30 mmHg for \> 70% of swallows and \> 50% peristaltic contractions on high resolution manometry. * Subject has signed the informed consent form. Exclusion Criteria: * Subject has non-GERD esophageal motility disorders. * Subject has gastroparesis. * Subject has significant multisystem diseases. * Subject has scleroderma requiring therapy in the preceding 2 years . * Subject has dermatomyositis requiring therapy in the preceding 2 years. * Subject has Calcinosis-Raynaud's-esophaguschlerodactyly syndrome requiring therapy in the preceding 2 years. * Subject has Sjogren's Syndrome requiring therapy in the preceding 2 years. * Subject has Sharp's Syndrome requiring therapy in the preceding 2 years. * Subject has persistent esophagitis greater than LA grade C. * Subject has Barrett's epithelium (\> M2; \>C1) or any dysplasia. * Subject has a hiatus hernia larger than 3 cm. * Subject has a body mass Index greater than 35 kg/m2 . * Subject has Type 1 diabetes mellitus * Subject has uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c \>9.5 in the previous 6 months, or has T2DM for \> 10 years. * Subject has an autoimmune disorder requiring therapy in the preceding 2 years. * Subject has suspected or confirmed esophageal or gastric cancer. * Subject has esophageal or gastric varices. * Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease. * Subject has an existing implanted electrical stimulator (e.g., pacemaker). * Subject requires chronic anticoagulant therapy. * Subject has dysphagia or esophageal peptic structure, excluding Schatzki's ring. * Subject is pregnant or intends to become pregnant during the trial period. * Subject is currently enrolled in other potentially confounding research. * Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial. * History of any malignancy in the last 2 years * History of previous esophageal or gastric surgery, including nissen fundoplication